摘要
糖尿病视网膜病变(DR)是常见的糖尿病微血管并发症之一,其发病机制复杂,涉及炎症和氧化应激,最终导致视网膜微血管病变和神经退行性改变。大量的临床和基础研究证据显示,二甲双胍可改善DR,延缓其发生和进展。二甲双胍可通过依赖和不依赖腺苷酸活化蛋白激酶途径,对视网膜微血管和视网膜细胞起到保护作用。二甲双胍还可以通过减轻氧化应激反应,调节线粒体能量代谢等,改善视网膜细胞自噬、凋亡和衰老,从而对视网膜起保护作用。二甲双胍的临床与基础研究为DR治疗提供了新思路,为药物研发提供了潜在的方向。本文就二甲双胍改善DR的临床和基础研究进展进行综述。
Diabetic retinopathy,one of the microvascular complications of diabetes,has become a leading cause of blindness in developed countries.The disease's pathogenesis is complex and involves inflammation and oxidative stress,which eventually lead to retinal microvascular disease and neurodegenerative changes.A large body of clinical and basic research evidence shows that metformin can improve diabetic retinopathy and delay its onset and progression.Metformin exerts protective effects on retinal microangiopathy and retinal cells via AMP-activated protein kinase-dependent and-independent pathways.Metformin can improve retinal cell autophagy,apoptosis and senescence by reducing the oxidative stress response and regulating mitochondrial energy metabolism.Metformin clinical and basic research provides a new approach to treating diabetic retinopathy and a potential direction for developing drugs.This article reviews the progress of clinical and basic research on metformin's protective effects against diabetic retinopathy.
作者
刘巨平(综述)
李筱荣(审校)
Liu Juping;Li Xiaorong(Tianjin Key Laboratory of Retinal Functions and Diseases,Tianjin Branch of National Clinical Research Center for Ocular Disease,Eye Institute and School of Optometry,Tianjin Medical University Eye Hospital,Tianjin 300384,China)
出处
《中华实验眼科杂志(中英文)》
北大核心
2025年第8期749-753,共5页
Chinese Journal Of Experimental Ophthalmology
基金
天津医科大学天津市高等学校基本科研业务费资助项目(2018KJ063)。
